Search
Powered By HealthLine
Health Tools
 Depression Basics
 Antidepressant Drug Info
 Depression Q&A
 Depression Support Groups
 Depression Related Disorders
Featured Conditions
 Depression
 Anxiety
 Sleep
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer

Patients should avoid taking the two drugs together, researchers say

By Steven Reinberg
HealthDay Reporter


Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Amenorrhea
Amniocentesis
Amniocentesis and CVS
More...

Related Healthscout Videos
 border=
Early Detection of Pancreatic Cancer: Medicine's Next Big Thing?
Scarless Thyroid Surgery
Beating Heart Surgery
Cancer Killer: Saving Faces - Saving Lives
More...

Related Animations
 border=
Bipolar Disorder Animation
Breast Reduction
Breast Self-Exam Video
Colon Cancer
More...

Related Drug Information
 border=
Actonel
Ambien
Avandia
Detrol LA
More...

Related News Articles
 border=
High Rates of Early Elective Delivery at Some U.S. Hospitals: Report
Healthier Lifestyles May Prevent 340,000 U.S. Cancers a Year: Study
Breast Cancer Treatment May Lead to Hip Fracture
The More Mom Works, the Heavier Her Kids Get: Study
More...

MONDAY, Feb. 8 (HealthDay News) -- Women with breast cancer who take both tamoxifen and the antidepressant Paxil may increase their risk of dying because Paxil reduces tamoxifen's effectiveness, Canadian researchers report.

"Paxil can deprive women of the benefit of tamoxifen, especially when it is used in combination with tamoxifen for a long time," said lead researcher Dr. David Juurlink, division head of clinical pharmacology and toxicology at Sunnybrook Health Sciences Center in Toronto.

Text Continues Below



"Patients who are on tamoxifen and who require an antidepressant should probably be given something different," he added.

Paroxetine (Paxil) is a selective serotonin reuptake inhibitor (SSRI) that significantly inhibits an enzyme called cytochrome P450 2D6, which is needed to metabolize tamoxifen into its active form. But this dampening effect was not seen with certain other SSRIs evaluated, including citalopram (Celexa) and venlafaxine (Effexor), the researchers said.

Patients taking Paxil and tamoxifen should talk with their doctors about changing their antidepressant, Juurlink said.

But he advised against abruptly discontinuing Paxil.

"There is a very real danger to stopping Paxil suddenly. There is a well-described withdrawal syndrome and the risk of depression becoming more severe," he said.

In addition, any transition to another antidepressant should be done gradually over several weeks, he said.

The report is published in the Feb. 8 online edition of the British Medical Journal.

For the study, Juurlink's group looked at the medical records of 2,430 women with breast cancer who began taking tamoxifen between 1993 and 2005. About 30 percent of the women were also taking an antidepressant, Paxil being the most common. Antidepressants are often prescribed to reduce hot flashes associated with tamoxifen in addition to easing symptoms of depression.

Page:  1 | 2 | Next >>

Copyright © 2010 HealthDay. All rights reserved.
Last updated 2/9/2010

Related Links
 border=
From Healthscout's partner site on depression, MyDepressionConnection.com
UNDERSTAND: Get a full understanding of depression
TREATMENT: Learn how therapy and lifestyle changes can help
DRUGS: Common drugs used to treat depression




SOURCES: David Juurlink, M.D., Ph.D., division head, clinical pharmacology and toxicology, Sunnybrook Health Sciences Center, Toronto; Frank Andersohn, M.D., senior research associate, Institute for Social Medicine, Epidemiology, and Health Economics, Charite University Medical Center, Berlin; Harold J. Burstein, M.D., Ph.D., clinical investigator, breast oncology center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and associate professor, medicine, Harvard Medical School, Boston; Feb. 8, 2009, British Medical Journal, online


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2011. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire